Does genotype-guided warfarin dosing reduce anticoagulation visits or improve time in therapeutic range in adults starting warfarin?
Genotype-guided warfarin dosing did not significantly improve time in therapeutic range or reduce the number of anticoagulation visits compared to clinical dosing alone.
AIM: This study aimed to assess the effectiveness of genotype-guided warfarin dosing. PATIENTS TTR: 0.40 vs 0.43, p = 0.59). Fewer emergency visits, hospitalizations, major hemorrhagic events, thrombotic events and deaths occurred in the genetic plus clinical group than in the clinical only group, but these differences were not statistically significant. CONCLUSION: Genotype-guided dosing did not decrease the number of anticoagulation visits or improve TTR. Our trial was not powered to detect anything but large differences for utilization and health outcomes.
Jonas et al. (Tue,) studied this question.